FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways

scientific article published on 06 December 2019

FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3389/FONC.2019.01306
P932PMC publication ID6908519
P698PubMed publication ID31867269

P2093author name stringMaría Florencia Mercogliano
Jaume Reventos
Antonio Gil-Moreno
Eva Colas
Mónica Hebe Vazquez-Levin
Lara Lapyckyj
María José Besso
María Laura Matos
Marina Rosso
Alejandra Wernicke
Roxana Schillaci
Cristian Pablo Moiola
Roberto Orti
P2860cites workGenevestigator v3: a reference expression database for the meta-analysis of transcriptomesQ21342839
Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasisQ24292072
Significance of Monocyte Counts at Recurrence on Survival Outcome of Women With Endometrial Cancer.Q46139173
Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expressionQ72999332
Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomasQ73032228
Significance of perivascular lymphocytic infiltrates in endometrial carcinomaQ73833548
Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosisQ79461944
Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinomaQ80490816
Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancerQ80933295
Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 casesQ80984978
Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinomaQ81170765
Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinomaQ81604936
Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significanceQ82363137
Involvement of dysadherin and E-cadherin in the development of testicular tumoursQ24651274
In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherinQ24653604
Dysadherin: a new player in cancer progressionQ24671729
Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an updateQ26779980
FXYD5 Is an Essential Mediator of the Inflammatory Response during Lung InjuryQ33747385
Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.Q33872622
Involvement of members of the cadherin superfamily in cancerQ33899441
Controversies in surgical staging of endometrial cancerQ33959822
Revised FIGO staging for carcinoma of the endometriumQ34016941
Molecular markers of endometrial carcinoma detected in uterine aspirates.Q34157607
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ34215306
Dysadherin: expression and clinical significance in thyroid carcinomaQ34229918
ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas.Q34248837
Two pathogenetic types of endometrial carcinomaQ34713298
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cellsQ35011812
Identification of a Novel Human E-Cadherin Splice Variant and Assessment of Its Effects Upon EMT-Related EventsQ36147466
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-upQ36372293
The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial CancerQ36764919
NF-kappaB as a potential molecular target for cancer therapyQ36870474
FXYD5 Protein Has a Pro-inflammatory Role in Epithelial CellsQ36987622
Expression and clinical significance of the transforming growth factor-β signalling pathway in endometrial cancerQ37305487
Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells.Q38337275
Prognostic implications of epithelial to mesenchymal transition related proteins (E-cadherin, Snail) and hypoxia inducible factor 1α in endometrioid endometrial carcinomaQ38770874
Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancersQ38825241
Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGFβ pathwayQ38970819
Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activationQ39365972
Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinomaQ39469755
High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasionQ39536386
ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer.Q40105517
Molecular diagnosis of endometrial cancer from uterine aspirates.Q44593249
Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.Q45104153
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P4510describes a project that usesImageJQ1659584
P921main subjectNF-κBQ411114
biomarkerQ864574
endometrial cancerQ944777
P304page(s)1306
P577publication date2019-12-06
P1433published inFrontiers in OncologyQ26839986
P1476titleFXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways
P478volume9